Bank of New York Mellon’s Kite Pharma, Inc. KITE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-231,794
| Closed | -$41.7M | – | 4474 |
|
|
2017
Q3 | $41.7M | Sell |
231,794
-22,530
| -9% | -$3.14M | 0.01% | 1099 |
|
|
2017
Q2 | $26.4M | Sell |
254,324
-671
| -0.3% | -$54.8K | 0.01% | 1374 |
|
|
2017
Q1 | $20M | Buy |
254,995
+49,752
| +24% | +$3.08M | 0.01% | 1551 |
|
|
2016
Q4 | $9.2M | Sell |
205,243
-2,228
| -1% | -$109K | ﹤0.01% | 1998 |
|
|
2016
Q3 | $11.6M | Sell |
207,471
-2,656
| -1% | -$148K | ﹤0.01% | 1796 |
|
|
2016
Q2 | $10.5M | Buy |
210,127
+8,655
| +4% | +$425K | ﹤0.01% | 1824 |
|
|
2016
Q1 | $9.25M | Buy |
201,472
+20,881
| +12% | +$1.01M | ﹤0.01% | 1871 |
|
|
2015
Q4 | $11.1M | Buy |
180,591
+26,578
| +17% | +$1.87M | ﹤0.01% | 1775 |
|
|
2015
Q3 | $8.58M | Buy |
154,013
+19,703
| +15% | +$1.24M | ﹤0.01% | 1948 |
|
|
2015
Q2 | $8.19M | Buy |
134,310
+65,370
| +95% | +$3.73M | ﹤0.01% | 2071 |
|
|
2015
Q1 | $3.98M | Buy |
68,940
+10,548
| +18% | +$707K | ﹤0.01% | 2443 |
|
|
2014
Q4 | $3.37M | Buy |
58,392
+29,452
| +102% | +$1.24M | ﹤0.01% | 2528 |
|
|
2014
Q3 | $825K | Buy |
+28,940
| New | +$716K | ﹤0.01% | 3398 |
|
Bank of New York Mellon's KITE Position: Q4 2017 in Review
Bank of New York Mellon sold out of Kite Pharma, Inc. (KITE) in Q4 2017, closing a stake of 231,794 shares — an estimated $41.7M sold.
Bank of New York Mellon first reported a position in KITE in Q3 2014 and held it in 13 quarters. The position peaked at $41.7M in Q3 2017. 0 funds tracked by Wall St. Rank hold KITE as of Q4 2017.
- Bank of New York Mellon reported no remaining Kite Pharma, Inc. position as of Q4 2017 after selling out during the quarter.
- Bank of New York Mellon sold 231,794 Kite Pharma, Inc. shares in Q4 2017, an estimated $41.7M.
- Bank of New York Mellon first reported a position in Kite Pharma, Inc. in Q3 2014 and held it in 13 quarters.
- Bank of New York Mellon's Kite Pharma, Inc. position peaked at $41.7M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q4 2017.
Based on Bank of New York Mellon's 13F filing for Q4 2017, filed 9 Feb 2018.